Trial
NCT03722186
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
Phase ISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborators
—
Condition
Physiological Effects of Drugs
Intervention
SHR-1603
Why stopped
Business Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-03-22